



International Journal of Pharmaceutical Research & Analysis

www.ijpra.com

Research article

ESTIMATION OF DIGOXIN IN ITS TABLET DOSAGE FORM

A. Linga Naik*, A. Kranthi, G.Priyanka, G.Sravani

Department of Pharmaceutical Analysis, Scient Institute of Pharmacy, Ibrahimpatnam, Hyderabad-501506, Telangana, India.

ABSTRACT

Digoxin belongs to a class of medications called cardiac glycosides. It works by affecting certain minerals (sodium and potassium) inside heart cells. This reduces strain on the heart and helps it maintain a normal, steady, and strong heartbeat. It is also used to treat certain types of irregular heartbeat (such as chronic atrial fibrillation). This UV-spectrophotometric technique is quite simple, accurate, precise, reproducible, and sensitive. The UV method has been developed for quantification of digoxin in tablet formulation. The validation procedure confirms that this is an appropriate method for their quantification in the formulation. It is also used in routine quality control of the formulations containing this entire compound.

Keywords: Digoxin, Tablet form, Estimation.

INTRODUCTION

Digoxin belongs to a class of medications called cardiac glycosides. It works by affecting certain minerals (sodium and potassium) inside heart cells. This reduces strain on the heart and helps it maintain a normal, steady, and strong heartbeat. It is also used to treat certain types of irregular heartbeat (such as chronic atrial fibrillation). Treating heart failure may help maintain your ability to walk and exercise and may improve the strength of your heart. Treating an irregular heartbeat can also improve your ability to exercise [1]. Although some effects of digoxin may be noticed soon after taking, it can take up to 7-14 days or longer after drug initiation or a dosage change for the full effects to be seen. 500 to 750 mcg usually produces a detectable effect in 0.5 to 2 hours with a maximal effect in 2 to 6 hours. Additional doses of 125 to 375 mcg may be given at 6 to 8 hour intervals until clinical evidence of an adequate effect is noted. The usual amount of tablets that a 70 kg patient requires to achieve 8 to 12 mcg/kg peak body stores is 750 to 1250 mcg.

Corresponding Author

A. Linga Naik

Department of Pharmaceutical Analysis, Scient Institute of Pharmacy, Ibrahimpatnam, Hyderabad - 501506, Telangana, India.

Email : angothulinganaik123@gmail.com

MATERIALS AND CHEMICALS

Digoxin was bought from sigma Aldrich ltd. All chemicals (distilled water, methanol) and reagents used were of analytical grade and purchased from Qualigens Fine Chemicals, Mumbai, India [2-3]. A Labindia UV-visible spectrophotometer (UV-T60-India) was used for all absorbance measurements with matched quartz cells.

METHODOLOGY

Preparation of standard stock solution

Accurately weighed 10 mg of digoxin was transferred to a 100 ml volumetric flask, dissolved in 20 ml distilled water by shaking manually for 10 min. The volume was adjusted with the same up to the mark to give the final strength, i.e. 100 µg/ml.

Estimation of wavelength maximum

Appropriate volume 0.5 ml of standard stock solution of digoxin was transferred into a 10 ml volumetric flask, diluted to a mark with distilled water to give concentration of 5 µg/ml (and also 10, 15 µg/ml). The resulting solution was scanned in the UV range (200–400 nm). In spectrum digoxin showed absorbance maximum at 283 nm [4-5].

Method Validation

The method was validated in terms of linearity, accuracy, precision, and ruggedness. Linearity study Different aliquots of digoxinin the range 0.5–3 ml were transferred into series of 10 ml volumetric flasks, and the volume was made up to the mark with distilled water to get concentrations 5, 10, 15, 20, 25, and 30 µg/ml, respectively. The solutions were scanned on a spectrophotometer in the UV range 200–400 nm. The spectrum was recorded at 287 nm. The calibration plot was constructed as concentration vs. absorbance [6-7].

Accuracy

To the pre analysed sample solutions, a known amount of standard stock solution was added at different levels, i.e. 50%, 100%, and 150%. The solutions were reanalyzed by the proposed method [8-9].

Precision

Precision of the method was studied as intraday and interday variations. Intraday precision was determined by analyzing the 10, 15 and 20 µg/ml of digoxin solutions for three times in the same day. Interday precision was determined by analyzing the 10, 15, and 20 µg/ml of digoxin solutions daily for 3 days over the period of week [11-14].

LOD AND LOQ

The sensitivity of measurements of digoxin by the use of the proposed method was estimated in terms of the limit of quantification (LOQ) and limit of detection (LOD). The LOQ and LOD were calculated using equation $LOD = 3 \times N/B$ and $LOQ = 10 \times N/B$, where 'N' is standard deviation of the peak areas of the drugs ($n = 3$), taken as a measure of noise, and 'B' is the slope of the corresponding calibration curve [15-16].

Repeatability

Repeatability was determined by analyzing 20 µg/ml concentration of digoxin solution for six times.

Ruggedness

Ruggedness of the proposed method is determined for 20 µg/ml concentration of digoxin by analysis of aliquots from a homogenous slot by two analysts using same operational and environmental conditions [17].

RESULTS & DISCUSSION

Selection of wavelength for analysis of digoxin. During the development phase, the use of ethanol as the diluent resulted in preferable outcome in UV analysis. The pre-determined wavelength of maximum absorption (λ_{max}) was 283 nm.

Table 1: solubility of drug in the solvents

S. No	Solvent	Amount (mcg/ml)
1	Pet ether	2.14
2	Chloroform	1.67
3	Methanol	0.99
4	Ethnaol	0.82
5	Acetone	0.73
6	Distilled water	0.51

Table 2: Estimation of accuracy and Recovery study

Parameter	Digoxin
Amount used	52mcg
Amount recovered	50.74mcg
Percentage recovered	99.87%
Label Claim	600mg
Estimated amount	499.12mg
Percentage of assay	99.1%

Table 3: Estimation of precision and other parameters

S. No	Parameters	values
1	max(nm)	283
2	linearity range	21-45µg/ml
3	regression equation	Y=0.0896X-0.0896
4	correlation coefficient	2.415
5	slope	0.0923
6	intercept	0.0867
7	Limit of detection(µg/ml)	0.9462

8	Limit of quantification($\mu\text{g/ml}$)	7.8765
10	Intra day variations	0.9892 \pm 0.0720
11	Inter day variations	0.9508 \pm 0.0384

CONCLUSION

This UV-spectrophotometric technique is quite simple, accurate, precise, reproducible, and sensitive. The UV method has been developed for quantification of digoxin in tablet formulation. The validation procedure confirms that this is an appropriate method for their

quantification in the formulation. It is also used in routine quality control of the formulations containing this entire compound.

CONFLICT OF INTEREST

Authors declare no conflict of interest.

REFERENCES

1. Indranil Chanda. Development and Validation of UV-Spectroscopic Method for Estimation of Niacin in Bulk and Pharmaceutical Dosage Form. *Journal of Applied Pharmaceutical Science* Vol. 7 (09), pp. 081-084, September, 2017.
2. Hanan A.Merey et Validated chromatographic methods for the simultaneous determination of Mometasone furoate and formoterol fumarate dihydrate in a combined dosage form. *Bulletin of Faculty of Pharmacy, Cairo University Bulletin of Faculty of Pharmacy, Cairo University* Volume 54, Issue 1, June 2016, Pages 99-106.
3. K. Ganesh et al Development and Validation of UV Spectrophotometric Method for Simultaneous Estimation of Metformin and Glipizide in Tablet Dosage Form May 2016.
4. Pooja Z Gujarati, Krupa C Thala and Dilip G Maheshwari, Stability Indicating Hplc Method For Simultaneous Estimation Of Mometasone Furoate And formoterol fumarate dihydrate In Combined Dosage Form. *Pharmacophore* 2014, Vol. 5 (2), 219-230.
5. Rakshit Kanubhai Trivedi, Dhairyshil S.Chendake, Mukesh C.Patel, A Rapid, Stability-Indicating RP- HPLC Method for the Simultaneous Determination of Formoterol Fumarate, Tiotropium Bromide, and Ciclesonide in a Pulmonary Drug Product. *Sci Pharm.* 2012; 80: 591–603.
6. B.D Shah, S. Kumar, Y. C. Yadav, A.K. Seth, T. K. Ghelani, G. J. Deshmukh, Analytical Method Development And Method Validation of Tiotropium Bromide And Formoterol Fumarate Metered Dose Inhaler (Mdi) By Using RP-HPLC Method. *Asian Journal of Biochemical and Pharmaceutical Research*, 1(1), 2011.
7. Nandini Pai and Swapnali Suhas Patil, Development and validation of RP-HPLC method for estimation of formoterol fumarate and budesonide in pressurised meter dose inhaler form. *Der Pharmacia Sinica*, 2013, 4(4):15-25.
8. Katari Srinivasarao, Vinayk Gorule, Venkata Reddiah Ch and Venkata Krishna A, Validated Method Development for Estimation of Formoterol Fumarate and Mometasone Furoate in Metered Dose Inhalation Form by High Performance Liquid Chromatography. *J Anal Bioanal Techniques*, 2012, 3:7.
9. Indian Pharmacopoeia. Ghaziabad: The Indian Pharmacopoeia Commission, Govt of India, Ministry of Health and Family Welfare. 2007; 2: 1439.
10. Villines TC, Kim AS, Gore RS, Taylor AJ. Niacin: The evidence, clinical use, and future directions. *Curr Atheroscler Rep*, 2012; 14(1): 49-59.
11. Vasanthi R, Prasad J, Alagar Raja M, Prashanthi V, Shrisha V, David Banji, Selva Kumar D. Analytical method development and validation of lovastatin and niacin by using rp-hplc method. *Asian J Pharm Anal Med Chem* 2015; 3(3):128- 136.
12. Narayankar Savita M, Sakpal Promod H, Bhingare Chandrashekhar L, Ingale Pramod L. Development and validation of rphplc method for the estimation of rosuvastatin calcium and niacin in combined tablet dosage form. *Int J Pharm Res Rev*, 2015; 4(6):44-50.
13. Pravish Kumar Tiwari, Padmakar Sathe. Development and validation of HPTLC method for niacin and simvastatin in binary combination. *Adv Biosci Biotechnol*, 2010; 1:131-135.
14. Ranganath MK, Raja Ram Chowdary. Simultaneous estimation and validation of niacin and atorvastatin calcium by uv-spectroscopy in pure and tablet dosage form using methanol: water mixture as solvent. *RGUHS J Pharm Sci*, 2014; 4 (2):70-77.
15. Bratati Roy, Bhupinder Singh, Anjana Rizal CP Malik. Bioanalytical method development and validation of niacin and nicotinic acid in human plasma by LC–MS/MS. *Int J Pharm Clin Res*, 2014; 6(3): 206-213.
16. Dewani AP, Mohale DS, Hiware S, Bakal RL, Chandewar AV, Mohd Salimuddin Farooqui. Development and validation of rp-hplc method for simultaneous estimation of niacin and simvastatin in tablet dosage. *Indian J Pharm Pharmacol*, 2015; 2(1): 21-26.

17. Validation of analytical procedures: text and methodology, in: International Conference on Harmonization (ICH), Q2 (R1), IFPMA, Geneva, Switzerland, 2005.



Attribution-NonCommercial-NoDerivatives 4.0 International